HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sees R&D Rebound, Says FDA Safety Reviews “Not Inappropriate”

Executive Summary

Refinements to pharmaceutical industry pipelines during the Clinton healthcare reform era are about to pay off in a wave of new product launches, Pfizer CEO Hank McKinnell told investors at the Bear Stearns healthcare conference in New York City Sept. 17
Advertisement

Related Content

FDA Is “Conservative” On Safety, But “Appropriately So,” Pfizer Says
Pfizer Stops Swinging For The Fences; Combo Products Are Big Opportunity
FDA Sees Drug Discovery Technology, Mergers Cutting Down On NDAs
FDA Faster Approval Times For 2002 NMEs Aided By Resubmissions
Merck Leads Rebound In Rx Stocks; Upbeat Finish To Historic Bad Year
Novartis E-Trial Program Will Help Reduce Clinical Trial Personnel By 25%
Pfizer Crafting Industry Image Campaign Outside Of PhRMA
Pfizer Crafting Industry Image Campaign Outside Of PhRMA
NDA Filing Slowdown Continues; FDA Has Received 16 NMEs In FY 2002
R&D Cost Increase May Reflect Comparative Trials; Can Biotech Keep Up?
Advertisement
UsernamePublicRestriction

Register

PS040516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel